表皮调节素EREG在新生隐球菌穿越血脑屏障机制中的作用研究

中国真菌学杂志　 2023, Vol. 18 　Issue (4): 310-314.

表皮调节素EREG在新生隐球菌穿越血脑屏障机制中的作用研究

赵静宇¹, 刘意抒², 丁俊丽¹, 高杨杰¹, 徐乐臻¹, 廖万清³, 方伟⁴, 顾菊林¹

1. 上海东方肝胆外科医院皮肤科, 上海 200438;
2. 上海东方肝胆外科医院内科教研室, 上海 200438;
3. 上海长征医院皮肤科, 上海市医学真菌分子生物学重点实验室, 上海 200003;
4. 上海市第九人民医院激光美容科, 上海 200125

收稿日期:2022-11-09 出版日期:2023-08-28 发布日期:2023-09-02
通讯作者: 顾菊林,wujgjl@126.com;方伟,weifang081782@163.com E-mail:wujgjl@126.com;weifang081782@163.com
作者简介:赵静宇,女(满族),硕士,主治医师.E-mail:zjyhzq@126.com;刘意抒,女(汉族),本科,主管护师,E-mail:yishu1128@163.com
基金资助:
国家自然科学基金青年培育项目(2021GZR007);医工交叉研究青年培育项目(2021YGJC004);国家自然科学基金(81772159,82072259)

Mechanisms of EREG incryptococcal traversal of the blood-brain barrier

ZHAO Jingyu¹, LIU Yishu², DING Junli¹, GAO Yangjie¹, XU Lezhen¹, LIAO Wanqing³, FANG Wei⁴, GU Junlin¹

1. Department of Dermatology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China;
2. Teaching and Research section, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China;
3. Shanghai key laboratory of Molecular Mycology, Department of Dermatology, Chang zheng Hospital, Shanghai 200003, China;
4. Department of Laser and Aesthetic Medicine, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received:2022-11-09 Online:2023-08-28 Published:2023-09-02

摘要/Abstract

摘要： 目的测定新生隐球菌侵染血脑屏障过程中表皮调节素EREG(epiregulin)的表达量,探讨EREG在隐球菌穿越血脑屏障过程中的作用。方法利用新生隐球菌与Transwell小室构建体外血脑屏障模型,以PBS(phosphate buffered solution)为对照组,按照新生隐球菌感染时间分为感染3 h、6 h、12 h三组,通过检测不同感染时间Transwell上室单细胞跨膜电阻及下室菌悬液涂布来判断新生隐球菌对血脑屏障的黏附及穿透能力的改变,并应用western-blot检测该过程中血管内皮细胞EREG的表达量。结果随着感染时间延长,新生隐球菌对血管内皮细胞的感染程度加剧,穿透血脑屏障的数量增多,血管内皮细胞EREG的表达水平显著增加。结论新生隐球菌穿越血脑屏障的能力与EREG的表达水平有密切的关系。

关键词: 新生隐球菌, EREG, 血脑屏障

Abstract: Objective To determine the expression level of EREG in the blood-brain barrier infected by Cryptococcus neoformans and to explore the role of EREG crossing the blood-brain barrier. Methods To construct the model of blood brain barrier in vitro by using Cryptococcus neoformans and Transwell chamber, and PBS was used as the control group. According to the time of Cryptococcus infection, divided into three groups: 3 h, 6 h and 12 h. The changes of the adhesion and penetration ability of Cryptococcus to the blood-brain barrier were detected by detecting the transmembrane resistance of single cells in the upper chamber of the Transwell and the suspension coating in the lower chamber of the Transwell at different time of infection, and the expression level of EREG in vascular endothelial cells during the process was detected. Results The expression of EREG was significantly increased and positively correlated with the time of infection during the course of cryptococcal infection with microvascular endothelial cells. Conclusion These results indicated that the ability of Cryptococcus to cross the blood-brain barrier was closely related to the expression level of EREG.

Key words: Cryptococcus neoformans, EREG, blood-brain barrier

中图分类号:

R379.5

赵静宇, 刘意抒, 丁俊丽, 高杨杰, 徐乐臻, 廖万清, 方伟, 顾菊林. 表皮调节素EREG在新生隐球菌穿越血脑屏障机制中的作用研究[J]. 中国真菌学杂志, 2023, 18(4): 310-314.

ZHAO Jingyu, LIU Yishu, DING Junli, GAO Yangjie, XU Lezhen, LIAO Wanqing, FANG Wei, GU Junlin. Mechanisms of EREG incryptococcal traversal of the blood-brain barrier[J]. Chinese Journal of Mycology, 2023, 18(4): 310-314.

参考文献

[1] ZHAO Y, LIN X. Cryptococcus neoformans: Sex, morphogenesis, and virulence[J]. Infect Genet Evol, 2021,89: 104731.DOI: 10.1016/j.meegid.2021.104731.
[2] CHOW B W, GU C. The molecular constituents of the blood-brain barrier[J]. Trends Neurosci,2015,38(10): 598-608.
[3] PULZOVA L, BHIDE M R, ANDREJ K. Pathogen translocation across the blood-brain barrier[J]. FEMS Immunol Med Microbiol,2009, 57(3): 203-213.
[4] FANG W, FA Z Z, XIE Q, et al. Complex roles of annexin A2 in host blood-brain barrier invasion by Cryptococcus neoformans[J]. CNS Neurosci Ther,2017,23(4): 291-300.
[5] SHETTY P, BARGALE A, PATIL B R, et al. Cell surface interaction of annexin A2 and galectin-3 modulates epidermal growth factor receptor signaling in Her-2 negative breast cancer cells[J]. Mol Cell Biochem, 2016,411(1-2): 221-233.
[6] GUPTA G P, NGUYEN D X, CHIANG A C, et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis[J]. Nature, 2007,446(7137): 765-770.
[7] RIESE D J 2ND, CULLUM R L. Epiregulin: roles in normal physiology and cancer[J]. Semin Cell Dev Biol,2014,28: 49-56.DOI: 10.1016/j.semcdb.2014.03.005.
[8] PARK B J, WANNEMUEHLER K A, MARSTON B J, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS[J]. AIDS,2009,23(4): 525-530.
[9] CRAWFORD C J, CORDERO R, GUAZZELLI L, et al. Exploring Cryptococcus neoformans capsule structure and assembly with a hydroxylamine-armed fluorescent probe[J]. J Biol Chem,2020,295(13): 4327-4340.
[10] TOPLIS B, BOSCH C, SCHWARTZ I S, et al. The virulence factor urease and its unexplored role in the metabolism of Cryptococcus neoformans[J]. FEMS Yeast Res, 2020,20(4):foaa031.
[11] MARUVADA R, ZHU L, PEARCE D, et al. Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier[J]. Cell Microbiol,2012,14(10): 1544-1553.
[12] HARADA M, KAMIMURA D, ARIMA Y, et al. Temporal expression of growth factors triggered by epiregulin regulates inflammation development[J]. J Immunol,2015, 194(3): 1039-1046.
[13] DRAPER B K, KOMURASAKI T, DAVIDSON M K, et al. Epiregulin is more potent than EGF or TGFalpha in promoting in vitro wound closure due to enhanced ERK/MAPK activation[J]. J Cell Biochem, 2003, 89(6): 1126-1137.
[14] TAKAHASHI M, HAYASHI K, YOSHIDA K, et al. Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells[J]. Circulation,2003,108(20): 2524-2529.
[15] CAO Y, SHI R, YANG H, et al. Epiregulin promotes osteogenic differentiation and inhibits neurogenic trans-differentiation of adipose-derived mesenchymal stem cells via MAPKs pathway[J]. Cell Biol Int,2020,44(4): 1046-1058.
[16] 孟云芳, 法振宗, 方伟,等. 隐球菌感染体外血脑屏障模型的构建与应用[J]. 中国真菌学杂志, 2015, 10(2): 92-95.
[17] VERMA V, KHOURY S, PARISIEN M, et al. The dichotomous role of epiregulin in pain[J]. Pain,2020,161(5): 1052-1064.
[18] SUNAGA N, KAIRA K. Epiregulin as a therapeutic target in non-small-cell lung cancer[J]. Lung Cancer (Auckl),2015,6: 91-98. DOI:10.2147/LCTT.S60427.
[19] SEGOVIA-MENDOZA M, DÍAZ L, GONZÁLEZ-GONZÁLEZ M E, et al. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells[J]. J Steroid Biochem Mol Biol,2015,148: 122-131. DOI:10.1016/j.jsbmb.2014.12.006.